Singapore markets closed

Eupraxia Pharmaceuticals Inc. (EPRX.TO)

Toronto - Toronto Real-time price. Currency in CAD
Add to watchlist
2.3700+0.0700 (+3.04%)
As of 01:19PM EDT. Market open.
Currency in CAD

Valuation measures4

Market cap (intra-day) 48.56M
Enterprise value 23.13M
Trailing P/E N/A
Forward P/E N/A
PEG Ratio (5 yr expected) N/A
Price/sales (ttm)N/A
Price/book (mrq)1.97
Enterprise value/revenue N/A
Enterprise value/EBITDA -1.33

Trading information

Stock price history

Beta (5Y monthly) N/A
52-week change 3-17.86%
S&P500 52-week change 3-16.45%
52-week high 33.0000
52-week low 30.8000
50-day moving average 31.4290
200-day moving average 31.6141

Share statistics

Avg vol (3-month) 323.83k
Avg vol (10-day) 326.56k
Shares outstanding 521.39M
Implied shares outstanding 6N/A
Float 812.87M
% held by insiders 112.70%
% held by institutions 124.03%
Shares short (14 Sept 2022) 45.38k
Short ratio (14 Sept 2022) 40.15
Short % of float (14 Sept 2022) 40.06%
Short % of shares outstanding (14 Sept 2022) 40.03%
Shares short (prior month 14 Aug 2022) 41.56k

Dividends & splits

Forward annual dividend rate 4N/A
Forward annual dividend yield 4N/A
Trailing annual dividend rate 30.00
Trailing annual dividend yield 30.00%
5-year average dividend yield 4N/A
Payout ratio 40.00%
Dividend date 3N/A
Ex-dividend date 4N/A
Last split factor 2N/A
Last split date 3N/A

Financial highlights

Fiscal year

Fiscal year ends 30 Dec 2021
Most-recent quarter (mrq)29 Jun 2022

Profitability

Profit margin 0.00%
Operating margin (ttm)0.00%

Management effectiveness

Return on assets (ttm)-29.58%
Return on equity (ttm)-74.10%

Income statement

Revenue (ttm)N/A
Revenue per share (ttm)N/A
Quarterly revenue growth (yoy)N/A
Gross profit (ttm)N/A
EBITDA -17.46M
Net income avi to common (ttm)-18.47M
Diluted EPS (ttm)-1.2720
Quarterly earnings growth (yoy)N/A

Balance sheet

Total cash (mrq)35.46M
Total cash per share (mrq)1.66
Total debt (mrq)10.02M
Total debt/equity (mrq)42.45
Current ratio (mrq)10.13
Book value per share (mrq)1.15

Cash flow statement

Operating cash flow (ttm)-13.64M
Levered free cash flow (ttm)-7.98M